Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) Overview 2019: A Third-Generation, Type II Glycoengineered, Humanized Anti-CD20 Monoclonal Antibody (MAb) -

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Jul 12, 2019 09:26 am

The "Gazyva" report has been added to's offering.

Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen expressed on the surface of pre-B and mature-B lymphocytes. Gazyva mediates B-cell lysis through engagement of immune effector cells, by direct cell death, and by activation of the complement cascade.

Due to its reduced fucose content, Gazyva exhibits increased antibody-dependent cellular cytotoxicity than Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) in vitro in human cancer cell lines, and improves survival in xenograft models of diffuse large B-cell lymphoma and mantle cell lymphoma. As opposed to Rituxan, which is a type I anti-CD20 MAb, this third-generation anti-CD20 MAb is a stronger inducer of direct cell death and antibody-dependent cellular cytotoxicity.

Type II anti-CD20 MAbs have also demonstrated less dependence on complement-dependent cytotoxicity, which is an immune response that involves a series of proteins known as the complement system. Complement activation by Rituxan has been associated with infusion-related side effects of the drug.

Analyst Outlook

Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) gained approval for the treatment of Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo)-refractory follicular lymphoma (FL) in combination with Treanda (bendamustine; Teva), followed by Gazyva monotherapy, in February 2016.

The drug is Roche's third-generation anti-CD20 monoclonal antibody (MAb), and is positioned as a potential replacement for Rituxan in the FL market. Gazyva will experience greater uptake with an anticipated label expansion into the lucrative first-line treatment setting, but the author believes that the drug's pricing strategy will be a major determinant for its success. Roche will have to balance the desire to maximize payback on its investment with its need to enhance its market penetration.

Key Topics Covered:


Drug Overview

Product Profiles

Gazyva: Chronic lymphocytic leukemia (CLL)

Gazyva: NHL: Follicular lymphoma (FL)

Gazyva: NHL: Mantle cell lymphoma (MCL)


Figure 1: The authors drug assessment summary of Gazyva for CLL

Figure 2: Gazyva sales for CLL across the US and five major EU markets, by country, 2017-26

Figure 3: Gazyva for follicular lymphoma - SWOT analysis

Figure 4: The authors drug assessment summary of Gazyva for follicular lymphoma

Figure 5: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 6: Gazyva for mantle cell lymphoma - SWOT analysis


Table 1: Gazyva drug profile

Table 2: Approval history of Gazyva for CLL in the US, Japan, and five major EU markets

Table 3: Trials of Gazyva for CLL

Table 4: Gazyva for CLL - SWOT analysis

Table 5: Gazyva drug profile

Table 6: Gazyva pivotal trial data in follicular lymphoma

Table 7: Gazyva other clinical trials in follicular lymphoma

Table 8: Gazyva ongoing late-phase clinical trials in follicular lymphoma

Table 9: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 10: Gazyva drug profile

Table 11: Gazyva Phase I/II data in mantle cell lymphoma

Table 12: Gazyva Phase Ib/II trial in mantle cell lymphoma

For more information about this report visit
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).